AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9113184 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 24
Study 8227488 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 58
Study 8227488 — intervention group
Group type: EXPERIMENTAL
Intervention: Desipramine
Number of subjects: 58
Study 2868812 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary propranolol (1.1 +/- 0.2 mg)
Number of subjects: 21
Study 2868812 — intervention group
Group type: COMPARATOR
Intervention: Intracoronary placebo (saline, 2 ml)
Number of subjects: 21
Study 30198863 — intervention group
Group type: EXPERIMENTAL
Intervention: Five up-regulated miRNAs (miR-200a-3p, miR-296-5p, miR-132-3p, miR-485-3p, and miR-22-5p) identified in serum of GCA patients
Number of subjects: 102
Study 30198863 — intervention group
Group type: EXPERIMENTAL
Intervention: GCA tissues
Number of subjects: 102
Study 30198863 — intervention group
Group type: COMPARATOR
Intervention: Exosomes
Number of subjects: 102
Study 26551659 — intervention group
Group type: EXPERIMENTAL
Intervention: Couple intervention (Marriage Checkup - MC)
Number of subjects: 244
Study 24290209 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 min of mild‐to‐moderate intensity exercise (EC; n=14)
Number of subjects: 30
Study 24290209 — intervention group
Group type: COMPARATOR
Intervention: Passive condition (PC; n=16)
Number of subjects: 30
Study 23053458 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-absorbable polypropylene mesh (Optilene® Mesh Elastic)
Number of subjects: 80
Study 23053458 — intervention group
Group type: COMPARATOR
Intervention: Partly absorbable mesh (Ultrapro® Mesh)
Number of subjects: 80
Study 23053458 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 80
Study 19711335 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram
Number of subjects: 198
Study 19711335 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 198
Study 17652214 — intervention group
Group type: EXPERIMENTAL
Intervention: LIPID (intralipid infusion at 20% at 90 ml/h plus heparin 200 U prime + 600 U/h)
Number of subjects: 10
Study 17652214 — intervention group
Group type: COMPARATOR
Intervention: CON (without intralipid infusion)
Number of subjects: 10
Study 17652214 — intervention group
Group type: EXPERIMENTAL
Intervention: LIPID
Number of subjects: 10
Study 17652214 — intervention group
Group type: EXPERIMENTAL
Intervention: LIPID and CON
Number of subjects: 10
Study 17652214 — intervention group
Group type: COMPARATOR
Intervention: CON
Number of subjects: 10
Study 16324159 — intervention group
Group type: EXPERIMENTAL
Intervention: Migraine diagnosis (IHS categories 1.1 and 1.2)
Number of subjects: 2500
Study 16324159 — intervention group
Group type: EXPERIMENTAL
Intervention: Other forms of episodic headache
Number of subjects: 2500
Study 16324159 — intervention group
Group type: EXPERIMENTAL
Intervention: Headache-free status
Number of subjects: 2500
Study 16324159 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequency and severity of headaches
Number of subjects: 2500
Study 14504812 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole solution
Number of subjects: 106
Study 14504812 — intervention group
Group type: COMPARATOR
Intervention: Amphotericin B solution
Number of subjects: 106
Study 10357538 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal accessory nerve transfer
Number of subjects: 205
Study 10357538 — intervention group
Group type: COMPARATOR
Intervention: Intercostal nerve transfer
Number of subjects: 205
Study 8602564 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil retard 360 mg/day
Number of subjects: 1073
Study 8602564 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1073
Study 1707230 — intervention group
Group type: COMPARATOR
Intervention: Low-dose Adriamycin (doxorubicin, 20 mg/m2) alone
Number of subjects: 61
Study 1707230 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination chemotherapy with bleomycin and vincristine (ABV)
Number of subjects: 61
Study 6762308 — intervention group
Group type: EXPERIMENTAL
Intervention: Riopan
Number of subjects: 10
Study 6762308 — intervention group
Group type: EXPERIMENTAL
Intervention: Maaloxan
Number of subjects: 10
Study 6762308 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 10
Study 3900236 — intervention group
Group type: EXPERIMENTAL
Intervention: 100,000 U aqueous penicillin G
Number of subjects: 53
Study 3900236 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 53
Study 30101333 — intervention group
Group type: EXPERIMENTAL
Intervention: DGA diet
Number of subjects: 52
Study 30101333 — intervention group
Group type: COMPARATOR
Intervention: TAD diet
Number of subjects: 52
Study 27654344 — intervention group
Group type: EXPERIMENTAL
Intervention: Point-of-care hemostatic testing
Number of subjects: 7402
Study 27654344 — intervention group
Group type: COMPARATOR
Intervention: Control phase (standard care)
Number of subjects: 7402
Study 24347034 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% ropivacaine
Number of subjects: 39
Study 24347034 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% ropivacaine
Number of subjects: 39
Study 24347034 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.75% ropivacaine
Number of subjects: 39
Study 22078076 — intervention group
Group type: EXPERIMENTAL
Intervention: Dementia care mapping
Number of subjects: 194
Study 22078076 — intervention group
Group type: EXPERIMENTAL
Intervention: Person centred care
Number of subjects: 194
Study 22078076 — intervention group
Group type: COMPARATOR
Intervention: Usual dementia care
Number of subjects: 194
Study 21246944 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyrantel tartrate
Number of subjects: 0
Study 21246944 — intervention group
Group type: EXPERIMENTAL
Intervention: Albendazole 2.5%
Number of subjects: 0
Study 21246944 — intervention group
Group type: EXPERIMENTAL
Intervention: Duramectin 1%
Number of subjects: 0
Study 18250181 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulised furosemide 40 mg
Number of subjects: 20
Study 16777503 — intervention group
Group type: EXPERIMENTAL
Intervention: Etidronate
Number of subjects: 0
Study 16777503 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 11472698 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate (MgSO(4); 40 mmol/24 hours)
Number of subjects: 15
Study 11472698 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 9595981 — intervention group
Group type: EXPERIMENTAL
Intervention: Amantadine
Number of subjects: 18
Study 9595981 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 8000815 — intervention group
Group type: EXPERIMENTAL
Intervention: 15% glucose solution (1 g kg‐1 body mass)
Number of subjects: 16
Study 8000815 — intervention group
Group type: COMPARATOR
Intervention: Low-energy sweetened placebo
Number of subjects: 16
Study 3291901 — intervention group
Group type: EXPERIMENTAL
Intervention: Split-course treatment (227 patients)
Number of subjects: 439
Study 3291901 — intervention group
Group type: COMPARATOR
Intervention: Continuous-course treatment (212 patients)
Number of subjects: 439
Study 29601271 — intervention group
Group type: EXPERIMENTAL
Intervention: Gain-framed message from an expert source with high number of 'likes'
Number of subjects: 0
Study 29601271 — intervention group
Group type: EXPERIMENTAL
Intervention: Gain-framed message
Number of subjects: 0
Study 29601271 — intervention group
Group type: EXPERIMENTAL
Intervention: Social endorsement and source type
Number of subjects: 0
Study 29601271 — intervention group
Group type: COMPARATOR
Intervention: Loss-framed message
Number of subjects: 0
Study 27027660 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-session psychoeducation treatment
Number of subjects: 67
Study 27027660 — intervention group
Group type: COMPARATOR
Intervention: Delayed treatment comparison control group
Number of subjects: 67
Study 24670774 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate removal (0h)
Number of subjects: 221
Study 24670774 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermediate removal (6h)
Number of subjects: 221
Study 24670774 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed removal (24h)
Number of subjects: 221
Study 21939626 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertonic saline infusion (HHS) 2 ml/kg (7.2% NaCl with 6% hydroxyethyl starch) over 10 min
Number of subjects: 203
Study 21939626 — intervention group
Group type: COMPARATOR
Intervention: HES infusion over 10 min
Number of subjects: 203
Study 20109196 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile phone-based care model for outpatient cardiac rehabilitation using ICT, including mobile phones with accelerometer sensors, WellnessDiary software, video and teleconferencing for mentoring, and educational multimedia content.
Number of subjects: 0
Study 20109196 — intervention group
Group type: COMPARATOR
Intervention: Traditional community-based rehabilitation program.
Number of subjects: 0
Study 18617492 — intervention group
Group type: EXPERIMENTAL
Intervention: Talking Parents, Healthy Teens (intervention)
Number of subjects: 569
Study 15946573 — intervention group
Group type: EXPERIMENTAL
Intervention: (188)Re-HEDP
Number of subjects: 48
Study 15946573 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamidronate
Number of subjects: 48
Study 15946573 — intervention group
Group type: EXPERIMENTAL
Intervention: (188)Re-HEDP plus pamidronate
Number of subjects: 48
Study 12017373 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 500 mg b.i.d.
Number of subjects: 20
Study 12017373 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 750 mg b.i.d.
Number of subjects: 20
Study 10215733 — intervention group
Group type: EXPERIMENTAL
Intervention: OAC (omeprazole 20 mg b.d., amoxycillin 1 g b.d., clarithromycin 500 mg b.d.)
Number of subjects: 308
Study 10215733 — intervention group
Group type: EXPERIMENTAL
Intervention: OMC (omeprazole 20 mg b.d., metronidazole 400 mg b.d., clarithromycin 250 mg b.d.)
Number of subjects: 308
Study 10215733 — intervention group
Group type: EXPERIMENTAL
Intervention: OAC
Number of subjects: 308
Study 10215733 — intervention group
Group type: EXPERIMENTAL
Intervention: OMC
Number of subjects: 308
Study 10215733 — intervention group
Group type: EXPERIMENTAL
Intervention: Second-line therapy (quadruple regimen: omeprazole 20 mg b.d., tripotassium dicitrato bismuthate 120 mg q.d.s., tetracycline 500 mg q.d.s., metronidazole 400 mg t.d.s.)
Number of subjects: 308
Study 10215733 — intervention group
Group type: EXPERIMENTAL
Intervention: Second-line therapy (2-week proton pump inhibitor-based triple therapy)
Number of subjects: 308
Study 10215733 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeat 1-week regimen
Number of subjects: 308
Study 10215733 — intervention group
Group type: EXPERIMENTAL
Intervention: Second-line therapy (1-week proton pump inhibitor-based triple therapy)
Number of subjects: 308
Study 7832264 — intervention group
Group type: EXPERIMENTAL
Intervention: Mentholated cigarettes
Number of subjects: 29
Study 7832264 — intervention group
Group type: COMPARATOR
Intervention: Non-mentholated cigarettes
Number of subjects: 29
Study 2242408 — intervention group
Group type: EXPERIMENTAL
Intervention: Progabide as an adjuvant therapy for partial seizures
Number of subjects: 0
Study 331503 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclophenac sodium (Voltaren)
Number of subjects: 69
Study 331503 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxyphenbutazone (Tanderil)
Number of subjects: 69
Study 331503 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study 31989505 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional training (CT) plus RAGT
Number of subjects: 51
Study 31989505 — intervention group
Group type: COMPARATOR
Intervention: Conventional training (CT)
Number of subjects: 51
Study 31989505 — intervention group
Group type: COMPARATOR
Intervention: RAGT
Number of subjects: 51
Study 30925953 — intervention group
Group type: EXPERIMENTAL
Intervention: Monosialoganglioside
Number of subjects: 90
Study 30925953 — intervention group
Group type: COMPARATOR
Intervention: Citicoline
Number of subjects: 90
Study 30294868 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzoyl peroxide + chlorhexidine/alcohol
Number of subjects: 22
Study 30294868 — intervention group
Group type: COMPARATOR
Intervention: Chlorhexidine/alcohol
Number of subjects: 22
Study 27085296 — intervention group
Group type: EXPERIMENTAL
Intervention: Locking intramedullary nails
Number of subjects: 72
Study 27085296 — intervention group
Group type: COMPARATOR
Intervention: Locking plates
Number of subjects: 72
Study 25496052 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive balance training program (4 weeks, twice a week) with wearable sensors providing visual/auditory feedback
Number of subjects: 33
Study 25496052 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive balance training program
Number of subjects: 33
Study 25496052 — intervention group
Group type: EXPERIMENTAL
Intervention: User experience of the training program
Number of subjects: 33
Study 25496052 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 33
Study 22266603 — intervention group
Group type: EXPERIMENTAL
Intervention: 48-week pegylated interferon (PEG-IFN) alfa-2a 180 mcg/week and ribavirin (RBV) 15mg/kg/day
Number of subjects: 105
Study 22266603 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-week pegylated interferon (PEG-IFN) alfa-2a 180 mcg/week and ribavirin (RBV) 15mg/kg/day
Number of subjects: 105
Study 19721059 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual cognitive-behavioral therapy (CBT)
Number of subjects: 180
Study 19721059 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined individual and group cognitive-behavioral therapy (CBT)
Number of subjects: 180
Study 19721059 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 180
Study 17709294 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin (BoNT-A) treatment
Number of subjects: 29
Study 17709294 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 29
Study 17709294 — intervention group
Group type: COMPARATOR
Intervention: Control group (10 subjects)
Number of subjects: 29
Study 16298160 — intervention group
Group type: EXPERIMENTAL
Intervention: Depot system (goserelin acetate, 'Zoladex')
Number of subjects: 82
Study 16298160 — intervention group
Group type: COMPARATOR
Intervention: Vial system (leuprorelin acetate, 'Prostap')
Number of subjects: 82
Study 12215937 — intervention group
Group type: EXPERIMENTAL
Intervention: 12.5 mg dolasetron
Number of subjects: 150
Study 12215937 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg lidocaine
Number of subjects: 150
Study 12215937 — intervention group
Group type: COMPARATOR
Intervention: Saline 0.9% as placebo
Number of subjects: 150
Study 10361663 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 mg intrathecal morphine sulfate
Number of subjects: 60
Study 10361663 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 mg intrathecal morphine sulfate
Number of subjects: 60
Study 10361663 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4 mg intrathecal morphine sulfate
Number of subjects: 60
Study 7572762 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ciprofloxacin plus penicillin V (group A)
Number of subjects: 108
Study 7572762 — intervention group
Group type: COMPARATOR
Intervention: Amikacin plus carbenicillin or ceftazidime (group B)
Number of subjects: 108
Study 2111784 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine (400 mg at night)
Number of subjects: 311
Study 2111784 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 311
Study 6265222 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized coarse wheat bran preparation, 0.5 kg‐1 body weight per day for 4 or 8 weeks
Number of subjects: 7
Study 6265222 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized coarse wheat bran preparation, 0.5 kg‐1 body weight per day for 4 weeks
Number of subjects: 7
Study 6265222 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized coarse wheat bran preparation, 0.5 kg‐1 body weight per day for 8 weeks
Number of subjects: 7
Study 30302577 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufficient exemplar training
Number of subjects: 78
Study 30302577 — intervention group
Group type: COMPARATOR
Intervention: Existing narrowly focused low-intensity intervention
Number of subjects: 78
Study 27714506 — intervention group
Group type: EXPERIMENTAL
Intervention: Consecutive balneological treatment for 2 weeks (10 sessions of hydrotherapy and mud pack therapy)
Number of subjects: 50
Study 27714506 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent balneological treatment for 5 weeks (10 sessions of hydrotherapy and mud pack therapy)
Number of subjects: 50
Study 25336596 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic Health Record (EHR) use
Number of subjects: 32
Study 25336596 — intervention group
Group type: COMPARATOR
Intervention: Paper chart use
Number of subjects: 32
Study 24529387 — intervention group
Group type: EXPERIMENTAL
Intervention: QoL assessment at baseline (P1)
Number of subjects: 66
Study 24529387 — intervention group
Group type: EXPERIMENTAL
Intervention: Recalibration then‐test (P3)
Number of subjects: 66
Study 24529387 — intervention group
Group type: EXPERIMENTAL
Intervention: Coping mechanisms by age group
Number of subjects: 66
Study 22303437 — intervention group
Group type: COMPARATOR
Intervention: CQ
Number of subjects: 308
Study 22303437 — intervention group
Group type: EXPERIMENTAL
Intervention: CQ+AS
Number of subjects: 308
Study 22303437 — intervention group
Group type: COMPARATOR
Intervention: SP
Number of subjects: 308
Study 22303437 — intervention group
Group type: EXPERIMENTAL
Intervention: SP+AS
Number of subjects: 308
Study 22303437 — intervention group
Group type: EXPERIMENTAL
Intervention: CQ+PQ
Number of subjects: 308
Study 22303437 — intervention group
Group type: EXPERIMENTAL
Intervention: SP+PQ
Number of subjects: 308
Study 22303437 — intervention group
Group type: EXPERIMENTAL
Intervention: AS
Number of subjects: 308
Study 22303437 — intervention group
Group type: EXPERIMENTAL
Intervention: PQ
Number of subjects: 308
Study 19542238 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone therapy (Nebido)
Number of subjects: 13
Study 19542238 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 17498576 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus-Eluting Stent (SES)
Number of subjects: 320
Study 17498576 — intervention group
Group type: COMPARATOR
Intervention: Bare-Metal Stent (BMS)
Number of subjects: 320
Study 15825711 — intervention group
Group type: EXPERIMENTAL
Intervention: FGF 1 l.min(‐1)
Number of subjects: 77
Study 15825711 — intervention group
Group type: COMPARATOR
Intervention: FGF 2 l.min(‐1)
Number of subjects: 77
Study 11577783 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemabate (PGF2alpha)
Number of subjects: 529
Study 11577783 — intervention group
Group type: COMPARATOR
Intervention: Syntometrine (ergometrine and syntocinon)
Number of subjects: 529
Study 9613912 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized budesonide, 2 mg
Number of subjects: 198
Study 9613912 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral dexamethasone, 0.6 mg/kg
Number of subjects: 198
Study 9613912 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral dexamethasone, 0.6 mg/kg and nebulized budesonide, 2 mg
Number of subjects: 198
Study 9613912 — intervention group
Group type: COMPARATOR
Intervention: Oral placebo and nebulized placebo
Number of subjects: 198
Study 1312763 — intervention group
Group type: EXPERIMENTAL
Intervention: Guar (20 grams taken at breakfast)
Number of subjects: 8
Study 1312763 — intervention group
Group type: COMPARATOR
Intervention: Control (polysaccharide-free diet)
Number of subjects: 8
Study 1312763 — intervention group
Group type: EXPERIMENTAL
Intervention: Psyllium (20 grams taken at breakfast)
Number of subjects: 8
Study 3516755 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg sodium diclofenac tablet (Novapirina) every 12 hours for 2 consecutive days
Number of subjects: 120
Study 3516755 — intervention group
Group type: COMPARATOR
Intervention: 500 mg tablet of acetylsalicylic acid (Aspirin) every 8 hours for 2 consecutive days
Number of subjects: 120
Study 31334554 — intervention group
Group type: EXPERIMENTAL
Intervention: MedDiet + EVOO
Number of subjects: 100
Study 31334554 — intervention group
Group type: EXPERIMENTAL
Intervention: MedDiet + nuts
Number of subjects: 100
Study 31334554 — intervention group
Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 100
Study 29502065 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal mask (LAM) with 6% sevoflurane at 6 L/min for induction and 3% for maintenance
Number of subjects: 52
Study 29502065 — intervention group
Group type: COMPARATOR
Intervention: Tracheal intubation with 1.5 mg/kg propofol and 1 µg/kg remifentanil, followed by 0.9 mg/kg rocuronium
Number of subjects: 52
Study 29502065 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal mask (LAM)
Number of subjects: 52
Study 29502065 — intervention group
Group type: COMPARATOR
Intervention: Tracheal intubation
Number of subjects: 52
Study 26666649 — intervention group
Group type: EXPERIMENTAL
Intervention: TPF (docetaxel plus cisplatin and 5-fluorouracil)
Number of subjects: 75
Study 26666649 — intervention group
Group type: COMPARATOR
Intervention: PF (cisplatin and 5-fluorouracil)
Number of subjects: 75
Study 25561147 — intervention group
Group type: EXPERIMENTAL
Intervention: Sterol milk (Naturcol) for 3 weeks
Number of subjects: 35
Study 25561147 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 3 weeks
Number of subjects: 35
Study 22321162 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemiarthroplasty
Number of subjects: 0
Study 22321162 — intervention group
Group type: COMPARATOR
Intervention: Angle-stable locking compression plate osteosynthesis
Number of subjects: 0
Study 21147728 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran 110 mg BID (D110)
Number of subjects: 18113
Study 21147728 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran 150 mg BID (D150)
Number of subjects: 18113
Study 21147728 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 18113
Study 17156341 — intervention group
Group type: EXPERIMENTAL
Intervention: CAP-FEIA system (Phadia)
Number of subjects: 45
Study 17156341 — intervention group
Group type: EXPERIMENTAL
Intervention: RAST (radioallergosorbent test)
Number of subjects: 45
Study 17156341 — intervention group
Group type: EXPERIMENTAL
Intervention: RAST in patients with anaphylactic shock and negative skin tests
Number of subjects: 45